• 1
    Vogel CL,Cobleigh MA,Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. JClin Oncol. 2002; 20: 719726.
  • 2
    Slamon DJ,Leyland-Jones B,Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl JMed. 2001; 344: 783792.
  • 3
    Kakar S,Puangsuvan N,Stevens JM, et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn. 2000; 5: 199207.
  • 4
    Pauletti G,Dandekar S,Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. JClin Oncol. 2000; 18: 36513664.
  • 5
    Wolff AC,Hammond ME,Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007; 131: 1843.
  • 6
    Gu M,Ghafari S,Zhao M. Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens. Acta Cytol. 2005; 49: 471476.
  • 7
    Beatty BG,Bryant R,Wang W, et al. HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol. 2004; 122: 246255.
  • 8
    Moore JG,To V,Patel SJ, et al. HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparison with companion tissue sections. Diagn Cytopathol. 2000; 23: 299302.
  • 9
    Nizzoli R,Guazzi A,Naldi N, et al. HER-2/neu evaluation by fluorescence in situ hybridization on destained cytologic smears from primary and metastatic breast cancer. Acta Cytol. 2005; 49: 2730.
  • 10
    Bozzetti C,Personeni N,Nizzoli R, et al. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer (Cancer Cytopathol). 2003; 99: 310315.
  • 11
    Mezzelani A,Alasio L,Bartoli C, et al. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer. 1999; 80: 519525.
  • 12
    Klijanienko J,Couturier J,Galut M, et al. Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of HER-2/neu gene amplification in breast cancer fine-needle samples. Cancer (Cancer Cytopathol). 1999; 87: 312318.
  • 13
    Bofin AM,Ytterhus B,Martin C, et al. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol. 2004; 122: 110119.
  • 14
    Perez EA,Roche PC,Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002; 77: 148154.
  • 15
    McCormick SR,Lillemoe TJ,Beneke J, et al. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol. 2002; 117: 935943.
  • 16
    Bose S,Mohammed M,Shintaku P, et al. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/HER-2/NEU polysomy. Breast. J. 2001; 7: 337344.
  • 17
    Wang S,Hossein Saboorian M,Frenkel EP, et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol. 2002; 15: 137145.
  • 18
    Varshney D,Zhou YY,Geller SA, et al. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol. 2004; 121: 7077.
  • 19
    Grushko TA,Blackwood MA,Schumm PL, et al. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res. 2002; 62: 14811488.
  • 20
    Grushko TA,Dignam JJ,Das S, et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res. 2004; 10: 499507.